Arbutus Biopharma
ABUS
ABUS
71 hedge funds and large institutions have $92.6M invested in Arbutus Biopharma in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 22 increasing their positions, 20 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
59% less capital invested
Capital invested by funds: $227M → $92.6M (-$135M)
64% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 25
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
71
Holding in Top 10
–
Calls
$798K
Puts
$621K
Top Buyers
| 1 | +$7.85M | |
| 2 | +$1.92M | |
| 3 | +$961K | |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$946K |
| 5 |
B
Bailard
Foster City,
California
|
+$559K |
Top Sellers
| 1 | -$4.7M | |
| 2 | -$4.19M | |
| 3 | -$3.24M | |
| 4 |
Jennison Associates
New York
|
-$2.55M |
| 5 |
SCM
Sio Capital Management
New York
|
-$1.56M |